Philadelphia, Pennsylvania--(Newsfile Corp. - March 8, 2025) - Grabar Law Office is investigating claims on behalf of Sage Therapeutics, Inc. (NASDAQ: SAGE) shareholders. The investigation concerns whether certain officers and directors of Sage Therapeutics breached the fiduciary duties they owed to the company.
If you are a current Sage Therapeutics, Inc. (NASDAQ: SAGE) who purchased or acquired Sage Therapeutics shares prior to April 12, 2021, you can seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever.Please visit https://grabarlaw.com/the-latest/sage-shareholder-investigation/, email jgrabar@grabarlaw.com, or call us at 267-507-6085.
Why? In May 2022, Sage announced that it had initiated a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for zuranolone in the treatment of MDD. In June 2022, Sage announced that, rather than filing separate NDAs for zuranolone in the treatment of MDD and PPD, as originally intended, it would instead submit a single NDA seeking approval of zuranolone for the treatment of both MDD and PPD. In December 2022, Sage announced the completion of the rolling submission of the Zuranolone NDA to the FDA.
An underlying securities fraud class action complaint alleges that Sage Therapeutics, via certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) zuranolone was less effective in treating MDD than Defendants had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone's clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating MCI due to PD than Defendants had led investors to believe; (iv) accordingly, SAGE-718's clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated; (v) SAGE-324 was less effective in treating ET than Defendants had led investors to believe; (vi) accordingly, SAGE-324's clinical, regulatory, and commercial prospects as a treatment for ET were overstated; and (vii) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.
What You Can Do Now:If you purchased Sage Therapeutics shares prior to April 12, 2021 and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/sage-shareholder-investigation/ contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You may be able to seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #SageTherapeutics $SAGE
Attorney Advertising Disclaimer
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243865
